Emmes is excited to share the significant progress being made in clinical studies we undertake for clients and to give you a look inside some of our own news.
The pandemic revved up business for Emmes CEO Christine Dingivan. So she found balance with yoga.
Christine Dingivan’s first job delivering newspapers in junior high school was “a terrible experience,” she said, requiring a 2 a.m. wake-up call and, at times, her dad when her bike proved inefficient in Long Island, New York. Her dream to become a professional athlete also didn’t pan out, causing her family to encourage a pursuit in academics instead.
Emmes Employees Co-Author Substance Use Article for the New England Journal of Medicine
Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced its contribution to a study for the National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) and a related article published in the New England Journal of Medicine. Emmes statisticians Gaurav Sharma, Ph.D., and Aimee Wahle were co-authors of the article, “Bupropion and Naltrexone in Methamphetamine Use Disorder.”
Emmes Employees Contribute to New England Journal of Medicine Report on Pregnant Women with Epilepsy
Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced the company’s involvement in a recent article published in the New England Journal of Medicine. Emmes’ Carrie Brown and Dr. Steffanie Wilson were among the team of researchers who contributed to the article, “Changes in Seizure Frequency and Antiepileptic Therapy during Pregnancy.”
Emmes Leads Clinical Trials to Improve Pediatric Drug Labeling
Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced significant progress in its role as Data Coordinating Center for studies conducted under the Best Pharmaceuticals for Children Act (BPCA). Results from the Emmes-managed clinical trials, conducted through the BPCA Clinical Coordinating Center at Pediatric Trials Network, contributed directly to improved drug labeling for a range of products used in treating infants and children.
Neox acquired by Emmes
Neox acquired by Emmes
Emmes changes its structure, makes its first acquisition — and has more on tap for 2021
Dr. Christine Dingivan has stood in the top slot at Emmes for fewer than four months. In that time, she's led the Rockville life sciences services firm through its first acquisition and split the business into two units to, she said, better position it for further growth.And there’s more to come.
Paul VanVeldhuisen, Ph.D., Named President of Emmes’ New Public Sector Group
Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that long-time employee, Dr. Paul VanVeldhuisen, has been named President of Emmes Public Sector. Emmes is now organized into two business groups: Emmes Public Sector and Emmes Biopharma. The public sector group includes all the company’s existing federal government clients and contracts, as well as work for foundations, public/private sector partnerships, and not-for-profit organizations.
Emmes Acquires Neox s.r.o., a Clinical Research Organization Headquartered in the Czech Republic
Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that it has acquired Neox s.r.o., a European-based CRO. Neox will add over 150 employees who support biotechnology, pharmaceutical, and medical device companies. “This is an important and exciting step for Emmes, demonstrating significant progress on our strategic plans to grow our biopharmaceutical business,” said Dr. Christine Dingivan, Chief Executive Officer of Emmes. “Neox adds a sizable, well-established biopharmaceutical research services business to Emmes and significantly expands our international presence.”
Emmes Announces its Contribution to Second Remdesivir Clinical Trial for COVID-19
Emmes today announced that it has conducted the data and statistical analysis for the second iteration of the Adaptive COVID-19 Treatment Trial (ACTT-2). The ACTT-2 trial assessed the efficacy and safety of a 4-mg dose of baricitinib with remdesivir, versus remdesivir alone, in hospitalized COVID-19 patients. Baricitinib, produced by Eli Lilly and Company, has been used to treat adults with moderate to severe rheumatoid arthritis. Baricitinib, in combination with remdesivir for COVID-19 patients, received Emergency Use Authorization on November 19.
Emmes Employees Co-Author COVID-19 Vaccine Report for the New England Journal of Medicine
Emmes today announced that it provided the data and statistical analysis support for a Phase 1 clinical trial of an investigational COVID-19 vaccine, mRNA-1273, that enrolled adult volunteers. The results of this clinical trial were published in the New England Journal of Medicine (NEJM) on September 29. Three Emmes employees were among the co-authors of the recent report, “Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.” The employees are Jim Albert, lead project manager; Dr. Mat Makowski, senior biostatistician; and Kaitlyn Cross, senior biostatistician.
Life sciences firm’s new CEO talks expansion plans during Covid-19 pandemic
Dr. Christine Dingivan, Emmes president and CEO, was recently interviewed by Washington Business Journal reporter Sara Gilgore. In the interview Christine talks about her vision for the company, growth opportunities, and the company's strengths. She also discusses how the current COVID-19 pandemic has impacted the drug development industry, both short term and long term.
Emmes Selected as Corporate Achievement Award Winner by the Montgomery County Chamber of Commerce
Emmes today announced that the Montgomery County Chamber of Commerce has selected Emmes as the recipient of its 2020 Corporate Achievement Award. Dr. Anne Lindblad, who recently retired as the company’s president and chief executive officer, accepted the award at a virtual event hosted by the chamber on October 29. According to Lowell Yoder, chairman of the Montgomery County Chamber of Commerce and M&T Bank’s group vice president for the Greater Washington Market, “Over the years, Emmes has set high standards for financial performance, sound management, and sustained growth – while contributing significantly to our community along the way.”